dual anti-CHI3L1/anti-PD-1 bispecific antibody (Ocean Biomedical)

N/A

Report date: 2025/03/19 09:00:05

Base Information

Drug Namedual anti-CHI3L1/anti-PD-1 bispecific antibody (Ocean Biomedical)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionChitinase-3-like protein 1 inhibitorsProgrammed cell death protein 1 blockers
TargetsChitinase-3-like protein 1Programmed cell death protein 1
Therapy Area/IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungMelanoma +[4
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOcean Biomedical Inc
China Registration ClassN/A

Develop Information

Active CompaniesOcean Biomedical Inc
Inactive CompaniesN/A
Active IndicationsNeoplasm MetastasisCarcinoma, Non-Small-Cell LungMelanoma +[4
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A